ClotCare: Blood Clots, Stroke, Heart Attack
Monday, November 12, 2018
Home   |   DVT/PE   |   Blood Clots   |   Coumadin/Warfarin   |   New Patients   |   Self Testing   |   Email List   |   Donate

Pick a Topic:

Find info on a:

We subscribe to the HONcode principles of the HON Foundation. Click to verify.
ClotCare complies with the HONcode standard for trustworthy health
information:
verify here.

ClotCare is a member of the Coalition to Prevent Deep Vein Thrombosis (DVT Coalition)  ClotCare is a member organization of the Coalition to Prevent Deep Vein Thrombosis. Click here to learn more about the Coalition to Prevent Deep Vein Thrombosis and DVT Awareness Month, which is held each March.

Non-steroidal Anti-inflamatory Drugs (NSAIDs) Receive Greater Scrutiny in the Wake of Vioxx Withdrawal

Marie B. Walker
January 2005

As has been widely publicized in the major media outlets, the pharmaceutical company Merck pulled its non-steroidal anti-inflamatory drug (NSAID) Vioxx from the market in late September in response to a study indicating that the drug increases the risk of stroke and heart attack. Since the withdrawal of Vioxx, other drugs in this class have received greater scrutiny. Studies have suggested that drugs such as Celebrex, Bextra, and Aleve increase a patient's risk of stroke and heart attack. Below are links to news stories seen in the major media outlets relating to Celebrex, Bextra, and Aleve.

FDA Asks Pfizer to Stop Misleading Celebrex Ads

Read the story on Fox News
Read the story on CNN
Read the story on Reuters

Celebrex and Naproxen (Aleve) May Increase Stroke & Heart Attack Risk

Read the story on Fox News
Read the story on CNN
Read the story on Reuters
Ask a question about blood clots or anticoagulant medications Have questions? Ask ClotCare. Send questions by email to webmaster@clotcare.org.
ClotCare is a 501(c)(3) non-profit organization generously supported by your tax-deductible donations and grants from our industry supporters.
Blood Clot Activities Calendar

New Postings:

A Contrarian’s View on the 2018 Chest Guideline for Antithrombotic Therapy in Atrial Fibrillation

Click here to view full list of new postings
ClotCare Home | New Postings | Patient Postings | Clinician Postings | Join Our Email List | Useful Web Links
CE Opportunities | Training Programs | DVT & PE Stories | Editorial Board | Financial Support
About ClotCare | DVT Coalition | Donate to ClotCare | Contact Us
Key topics discussed on ClotCare include: Blood Clots | Deep Vein Thrombosis (DVT) | Pulmonary Embolism (PE) | Atrial Fibrillation (A. Fib or AF) | Heart Attack | Stroke | Transient Ischemic Attack (TIA) | Mini Stroke | Bleeding Complications | Vascular Surgery | Surgical Blood Clot Removal | Warfarin | Coumadin | Lovenox | Low Molecular Weight Heparin (LMWH) | Heparin | Anticoagulants | Plavix | Aspirin | Antiplatelets | Blood Thinners
Copyright 2000-2018 by ClotCare. All rights reserved.
Terms, Conditions, & Privacy | Image Copyright Information
19260 Stone Oak Parkway, Suite 101 | San Antonio, TX 78258 | 210-495-4335
Send comments to webmaster@clotcare.org.
Monday, November 12, 2018